Executive record

Paul Kim

Director at EXAGEN INC.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:paul-kimVersion: public-0As of: 2026-09-29

Not yet claimed9 published Claims3 sources
  • Director

Key Claims

Biography

Paul Kim has served as Chief Financial Officer of Fulgent Genetics, Inc. since February 2016. He brings extensive executive experience in finance and accounting, having served as CFO of multiple publicly traded companies in the life sciences and technology sectors. He is a Certified Public Accountant with experience in financial management and corporate operations.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: Chief Financial Officer · Organization not publishedXGN DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. XGN DEF 14A director slate

    sec filing · Source published: Apr 30, 2025 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit, Compensation · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Fulgent Genetics, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Financial Officer · Claim reviewed: May 16, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: May 16, 2026

  2. Open source

    sec proxy · Source published: Apr 30, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at EXAGEN INC. · Claim reviewed: May 16, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of EXAGEN INC. · Claim reviewed: May 16, 2026